PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31369645-3	2019	Here we examined sitravatinib (MGCD516), a spectrum-selective TKI able to block MET, TAM (TYRO3, AXL, MerTK) and multiple receptor families (including PDGFRs, VEGFRs, and Ephs).	sitravatinib	17-29	MER proto-oncogene, tyrosine kinase	Homo sapiens	102-107	
34599023-1	2021	BACKGROUND: Sitravatinib, a tyrosine kinase inhibitor that targets TYRO3, AXL, MERTK and the VEGF receptor family, is predicted to increase the M1 to M2-polarized tumor-associated macrophages ratio in the tumor microenvironment and have synergistic antitumor activity in combination with anti-programmed death-1/ligand-1 agents.	sitravatinib	12-24	MER proto-oncogene, tyrosine kinase	Homo sapiens	79-84	
31369645-3	2019	Here we examined sitravatinib (MGCD516), a spectrum-selective TKI able to block MET, TAM (TYRO3, AXL, MerTK) and multiple receptor families (including PDGFRs, VEGFRs, and Ephs).	sitravatinib	31-38	MER proto-oncogene, tyrosine kinase	Homo sapiens	102-107	
30385724-3	2018	Sitravatinib is a spectrum-selective tyrosine kinase inhibitor targeting TAM (TYRO3, AXL, MerTK) and split tyrosine-kinase domain-containing receptors (VEGFR and PDGFR families and KIT) plus RET and MET, targets that contribute to the immunosuppressive tumor microenvironment.	sitravatinib	0-12	MER proto-oncogene, tyrosine kinase	Homo sapiens	90-95